Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 123, Issue 3-5, 2011, Pages 140-150

  Englert, Neal A ^a,b   Spink, Barbara C ^a   Spink, David C ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

AhR; Breast cancer; Gene expression; Long term estrogen exposure; STAT1

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ESTRADIOL; GROWTH FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE; RALOXIFENE; STAT1 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA MICROARRAY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVATION; GENE CONTROL; GENE EXPRESSION; GREB1 GENE; HUMAN; HUMAN CELL; IF127 GENE; IFIT1 GENE; ISG15 GENE; PDZK1 GENE; PGR GENE; UPREGULATION;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; EPIGENOMICS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; STAT1 TRANSCRIPTION FACTOR;

EID: 79151478556     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.12.010     Document Type: Article

References (62)

1. M. Clemons, and P. Goss Estrogen and the risk of breast cancer N. Engl. J. Med. 344 4 2001 276 285
2. A. Clamp, S. Danson, and M. Clemons Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies Lancet Oncol. 3 10 2002 611 619
3. R.T. Chlebowski, L.H. Kuller, R.L. Prentice, M.L. Stefanick, J.E. Manson, M. Gass, A.K. Aragaki, J.K. Ockene, D.S. Lane, G.E. Sarto, A. Rajkovic, R. Schenken, S.L. Hendrix, P.M. Ravdin, T.E. Rohan, S. Yasmeen, and G. Anderson Breast cancer after use of estrogen plus progestin in postmenopausal women N. Engl. J. Med. 360 6 2009 573 587
4. R.T. Chlebowski, G.L. Anderson, M. Gass, D.S. Lane, A.K. Aragaki, L.H. Kuller, J.E. Manson, M.L. Stefanick, J. Ockene, G.E. Sarto, K.C. Johnson, J. Wactawski-Wende, P.M. Ravdin, R. Schenken, S.L. Hendrix, A. Rajkovic, T.E. Rohan, S. Yasmeen, R.L. Prentice, and for the WHI Investigators Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women JAMA 304 15 2010 1684 1692
5. M. Kumle Declining breast cancer incidence and decreased HRT use Lancet 372 9639 2008 608 610
6. V.C. Jordan Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions J. Med. Chem. 46 6 2003 883 908
7. M.D. Planas-Silva, and K.N. Hamilton Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins Cancer Chemother. Pharmacol. 60 4 2007 535 543
8. B. Fisher, J.P. Costantino, D.L. Wickerham, R.S. Cecchini, W.M. Cronin, A. Robidoux, T.B. Bevers, M.T. Kavanah, J.N. Atkins, R.G. Margolese, C.D. Runowicz, J.M. James, L.G. Ford, and N. Wolmark Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 97 22 2005 1652 1662
9. M.E. Lippman, K.A. Krueger, S. Eckert, A. Sashegyi, E.L. Walls, S. Jamal, J.A. Cauley, and S.R. Cummings Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants J. Clin. Oncol. 19 12 2001 3111 3116
10. J. Cuzick, J.F. Forbes, I. Sestak, S. Cawthorn, H. Hamed, K. Holli, and A. Howell Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial J. Natl. Cancer Inst. 99 4 2007 272 282
11. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, J.N. Atkins, T.B. Bevers, L. Fehrenbacher, E.R. Pajon Jr., J.L. Wade 3rd, A. Robidoux, R.G. Margolese, J. James, S.M. Lippman, C.D. Runowicz, P.A. Ganz, S.E. Reis, W. McCaskill-Stevens, L.G. Ford, V.C. Jordan, and N. Wolmark Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 23 2006 2727 2741
12. T. Wang, Q. You, F.S. Huang, and H. Xiang Recent advances in selective estrogen receptor modulators for breast cancer Mini Rev. Med. Chem. 9 10 2009 1191 1201
13. J.S. Strobl, W.F. Wonderlin, and D.C. Flynn Mitogenic signal transduction in human breast cancer cells Gen. Pharmacol. 26 8 1995 1643 1649
14. R.X. Song, P. Fan, W. Yue, Y. Chen, and R.J. Santen Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer Endocr. Relat. Cancer 13 Suppl. 1 2006 S3 13
15. S.F. Doisneau-Sixou, C.M. Sergio, J.S. Carroll, R. Hui, E.A. Musgrove, and R.L. Sutherland Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells Endocr. Relat. Cancer 10 2 2003 179 186
16. V. Rodrik, Y. Zheng, F. Harrow, Y. Chen, and D.A. Foster Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc Mol. Cell Biol. 25 17 2005 7917 7925
17. J.S. Lewis-Wambi, and V.C. Jordan Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 11 3 2009 206
18. A.S. Levenson, K.M. Svoboda, K.M. Pease, S.A. Kaiser, B. Chen, L.A. Simons, B.D. Jovanovic, P.A. Dyck, and V.C. Jordan Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor Cancer Res. 62 15 2002 4419 4426
19. E. Huang, S.H. Cheng, H. Dressman, J. Pittman, M.H. Tsou, C.F. Horng, A. Bild, E.S. Iversen, M. Liao, C.M. Chen, M. West, J.R. Nevins, and A.T. Huang Gene expression predictors of breast cancer outcomes Lancet 361 9369 2003 1590 1596
20. J.S. Carroll, C.A. Meyer, J. Song, W. Li, T.R. Geistlinger, J. Eeckhoute, A.S. Brodsky, E.K. Keeton, K.C. Fertuck, G.F. Hall, Q. Wang, S. Bekiranov, V. Sementchenko, E.A. Fox, P.A. Silver, T.R. Gingeras, X.S. Liu, and M. Brown Genome-wide analysis of estrogen receptor binding sites Nat. Genet. 38 11 2006 1289 1297
21. P. Bhat-Nakshatri, G. Wang, H. Appaiah, N. Luktuke, J.S. Carroll, T.R. Geistlinger, M. Brown, S. Badve, Y. Liu, and H. Nakshatri AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer Mol. Cell. Biol. 28 24 2008 7487 7503
22. K.C. Chang, Y. Wang, P.V. Bodine, S. Nagpal, and B.S. Komm Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens J. Steroid Biochem. Mol. Biol. 118 1-2 2010 117 124
23. J. Frasor, A. Weaver, M. Pradhan, Y. Dai, L.D. Miller, C.Y. Lin, and A. Stanculescu Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer Cancer Res. 69 23 2009 8918 8925
24. B.C. Spink, J.A. Bennett, B.T. Pentecost, N. Lostritto, N.A. Englert, G.K. Benn, A.K. Goodenough, R.J. Turesky, and D.C. Spink Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells Toxicol. Appl. Pharmacol. 240 3 2009 355 366
25. D.C. Spink, B.H. Katz, M.M. Hussain, B.T. Pentecost, Z. Cao, and B.C. Spink Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells Carcinogenesis 24 2003 1941 1950
26. I. Martinez-Lacaci, G.R. Johnson, D.S. Salomon, and R.B. Dickson Characterization of a novel amphiregulin-related molecule in 12-O-tetradecanoylphorbol-13-acetate-treated breast cancer cells J. Cell. Physiol. 169 3 1996 497 508
27. B.C. Spink, R.W. Cole, B.H. Katz, J.F. Gierthy, L.M. Bradley, and D.C. Spink Inhibition of MCF-7 breast cancer cell proliferation by MCF-10A breast epithelial cells in coculture Cell Biol. Int. 30 3 2006 227 238
28. S.J. Gobin, and P.J. van den Elsen Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G Hum. Immunol. 61 2000 1102 1107
29. Y. Zhang, Y.Y. Cho, B.L. Petersen, F. Zhu, and Z. Dong Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and MSK1 Carcinogenesis 25 7 2004 1165 1175
30. T. Heinemeyer, E. Wingender, I. Reuter, H. Hermjakob, A.E. Kel, O.V. Kel, E.V. Ignatieva, E.A. Ananko, O.A. Podkolodnaya, F.A. Kolpakov, N.L. Podkolodny, and N.A. Kolchanov Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL Nucleic Acids Res. 26 1 1998 362 367
31. T. Kisseleva, S. Bhattacharya, J. Braunstein, and C.W. Schindler Signaling through the JAK/STAT pathway, recent advances and future challenges Gene 285 1-2 2002 1 24
32. H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat. Rev. Cancer. 9 11 2009 798 809
33. R. Buettner, L.B. Mora, and R. Jove Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention Clin. Cancer Res. 8 4 2002 945 954
34. R.R. Weichselbaum, H. Ishwaran, T. Yoon, D.S. Nuyten, S.W. Baker, N. Khodarev, A.W. Su, A.Y. Shaikh, P. Roach, B. Kreike, B. Roizman, J. Bergh, Y. Pawitan, M.J. van de Vijver, and A.J. Minn An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer Proc. Natl. Acad. Sci. U.S.A. 105 47 2008 18490 18495
35. P.N. Span, R.L. Lindberg, P. Manders, V.C. Tjan-Heijnen, J.J. Heuvel, L.V. Beex, and C.G. Sweep Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success J. Pathol. 202 4 2004 395 402
36. J. Helleman, M.P. Jansen, K. Ruigrok-Ritstier, I.L. van Staveren, M.P. Look, M.E. Meijer-van Gelder, A.M. Sieuwerts, J.G. Klijn, S. Sleijfer, J.A. Foekens, and E.M. Berns Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response Clin. Cancer Res. 14 17 2008 5555 5564
37. S.A. Ochsner, D.L. Steffen, S.G. Hilsenbeck, E.S. Chen, C. Watkins, and N.J. McKenna GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells Cancer Res. 69 1 2009 23 26
38. X. Wang, S. Masri, S. Phung, and S. Chen The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop Cancer Res. 68 7 2008 2259 2265
39. E.R. Levin Minireview extranuclear steroid receptors: roles in modulation of cell functions Mol. Endocrinol. 2010 [Epub ahead of print]
40. Z. Madak-Erdogan, M. Lupien, F. Stossi, M. Brown, and B.S. Katzenellenbogen Genomic collaboration of estrogen Receptor-α and ERK2 in regulating gene and proliferation programs Mol. Cell. Biol. 31 1 2011 226 236
41. T. Bowman, R. Garcia, J. Turkson, and R. Jove STATs in oncogenesis Oncogene 19 21 2000 2474 2488
42. A.A. Habib, S.J. Chun, B.G. Neel, and T. Vartanian Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways Mol. Cancer Res. 1 3 2003 219 233
43. M.W. Pedersen, N. Pedersen, L. Damstrup, M. Villingshoj, S.U. Sonder, K. Rieneck, L.F. Bovin, M. Spang-Thomsen, and H.S. Poulsen Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation J. Cell. Biochem. 96 2 2005 412 427
44. L. Xia, L. Wang, A.S. Chung, S.S. Ivanov, M.Y. Ling, A.M. Dragoi, A. Platt, T.M. Gilmer, X.Y. Fu, and Y.E. Chin Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation J. Biol. Chem. 277 34 2002 30716 30723
45. F. He, W. Ge, K. Martinowich, S. Becker-Catania, V. Coskun, W. Zhu, H. Wu, D. Castro, F. Guillemot, G. Fan, J. de Vellis, and Y.E. Sun A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis Nat. Neurosci. 8 5 2005 616 625
46. H. Cheon, and G.R. Stark Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes Proc. Natl. Acad. Sci. U.S.A. 106 23 2009 9373 9378
47. A. Kimura, T. Naka, K. Nohara, Y. Fujii-Kuriyama, and T. Kishimoto Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells Proc. Natl. Acad. Sci. U.S.A. 105 28 2008 9721 9726
48. S. Li, K.A. Washburn, R. Moore, T. Uno, C. Teng, R.R. Newbold, J.A. McLachlan, and M. Negishi Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus Cancer Res. 57 19 1997 4356 4359
49. W.Y. Tang, R. Newbold, K. Mardilovich, W. Jefferson, R.Y. Cheng, M. Medvedovic, and S.M. Ho Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein Endocrinology 149 12 2008 5922 5931
50. T.G. Bredfeldt, K.L. Greathouse, S.H. Safe, M.C. Hung, M.T. Bedford, and C.L. Walker Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT Mol. Endocrinol. 24 5 2010 993 1006
51. J.A. Simpson, A. Al-Attar, N.F. Watson, J.H. Scholefield, M. Ilyas, L.G. Durrant, and Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer Gut 59 7 2010 926 933
52. X. He, D.D. Dong, S.M. Yie, H. Yang, M. Cao, S.R. Ye, K. Li, J. Liu, and J. Chen HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro Ann. Surg. Oncol. 17 2010 1459 1469
53. Z. Madjd, I. Spendlove, S.E. Pinder, I.O. Ellis, and L.G. Durrant Total loss of MHC class I is an independent indicator of good prognosis in breast cancer Int. J. Cancer 117 2 2005 248 255
54. K. Remes, A. Tienhaara, and T.T. Pelliniemi Effects of alpha-interferon on serum beta-2-microglobulin Leuk. Lymphoma 21 3-4 1996 233 238
55. S.E. Dovhey, N.S. Ghosh, and K.L. Wright Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line Cancer Res. 60 20 2000 5789 5796
56. M.C. Rouyez, M. Lestingi, M. Charon, S. Fichelson, A. Buzyn, and I. Dusanter-Fourt IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity J. Immunol. 174 7 2005 3948 3958
57. M. Teh, and K.M. Hui Modulation of MHC gene expression in human breast carcinoma cells by hormones J. Immunogenet. 16 4-5 1989 397 405
58. N.N. Khodarev, P. Roach, S.P. Pitroda, D.W. Golden, M. Bhayani, M.Y. Shao, T.E. Darga, M.G. Beveridge, R.F. Sood, H.G. Sutton, M.A. Beckett, H.J. Mauceri, M.C. Posner, and R.R. Weichselbaum STAT1 pathway mediates amplification of metastatic potential and resistance to therapy PLoS One 4 6 2009 e5821
59. D. Roberts, J. Schick, S. Conway, S. Biade, P.B. Laub, J.P. Stevenson, T.C. Hamilton, P.J. O'Dwyer, and S.W. Johnson Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells Br. J. Cancer 92 6 2005 1149 1158
60. M. Fryknas, S. Dhar, F. Oberg, L. Rickardson, M. Rydaker, H. Goransson, M. Gustafsson, U. Pettersson, P. Nygren, R. Larsson, and A. Isaksson STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines Int. J. Cancer 120 1 2007 189 195
61. N.N. Khodarev, A.J. Minn, E.V. Efimova, T.E. Darga, E. Labay, M. Beckett, H.J. Mauceri, B. Roizman, and R.R. Weichselbaum Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells Cancer Res. 67 19 2007 9214 9220
62. Z. Hui, M. Tretiakova, Z. Zhang, Y. Li, X. Wang, J.X. Zhu, Y. Gao, W. Mai, K. Furge, C.N. Qian, R. Amato, E.B. Butler, B.T. Teh, and B.S. Teh Radiosensitization by inhibiting STAT1 in renal cell carcinoma Int. J. Radiat. Oncol. Biol. Phys. 73 1 2009 288 295